['hepatitis c']
['cdi-31244', 'placebo']

        Main Inclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Male or female aged ≥ 18 to ≤ 65 years;

          -  Body mass index ≥ 18.5 to ≤ 35.0 kg/m2;

          -  Body weight ≥ 50 kg;

          -  Negative screening for alcohol and drugs of abuse;

          -  Normal results on 12-lead electrocardiogram (ECG);

          -  For females, negative result on a pregnancy test.

        HCV INFECTED SUBJECTS:

          -  HCV treatment-naïve subjects must have not received prior direct acting agent (DAA)
             treatment for hepatitis C infection;

          -  Documented clinical history compatible with chronic hepatitis C;

          -  HCV Genotype 1 by HCV genotyping performed at Screening;

          -  Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening;

          -  Laboratory evidence of no cirrhosis (negative liver biopsy or fibroscan or FibroTest,
             F2 or lower) within one year prior to study), if these are not available, do a
             FibroTest at screening, which must be F2 or lower.

        Main Exclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Females who are pregnant or are lactating;

          -  Co-infected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency
             virus (HIV);

          -  Abuse of alcohol and/or drugs that could interfere with adherence to study
             requirements as judged by the investigator;

          -  Positive screen result for drugs of abuse or alcohol on Day -1. Use of other
             investigational drugs within 60 days of dosing;

          -  Subject with intestinal malabsorption;

          -  Presence of out-of-range cardiac interval on the screening ECG or other clinically
             significant ECG abnormalities;

          -  Serum creatinine > upper limit of normal (ULN);

          -  Any clinically significant medical condition that, in the opinion of the investigator,
             would jeopardize the safety of the subject or impact the validity of the study
             results.

        HEALTHY VOLUNTEERS:

          -  Positive screen for anti-HCV antibody

        HCV INFECTED SUBJECTS:

          -  Clinical (in the opinion of the investigator) or laboratory evidence of cirrhosis;

          -  History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
             hypertension or hepatic insufficiency;

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC;

          -  Active clinically significant diseases.
      